Fusion Pharmaceuticals (NASDAQ:FUSN) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.
Institutional & Insider Ownership
61.4% of Fusion Pharmaceuticals shares are owned by institutional investors. Comparatively, 57.7% of Sangamo Therapeutics shares are owned by institutional investors. 1.8% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Fusion Pharmaceuticals and Sangamo Therapeutics' revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Fusion Pharmaceuticals | N/A | N/A | $-16,190,000.00 | N/A | N/A |
Sangamo Therapeutics | $102.43 million | 15.46 | $-95,190,000.00 | ($0.85) | -12.96 |
Fusion Pharmaceuticals has higher earnings, but lower revenue than Sangamo Therapeutics.
Analyst Recommendations
This is a summary of recent recommendations for Fusion Pharmaceuticals and Sangamo Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Fusion Pharmaceuticals | 0 | 0 | 5 | 0 | 3.00 |
Sangamo Therapeutics | 0 | 2 | 4 | 0 | 2.67 |
Fusion Pharmaceuticals currently has a consensus price target of $23.6667, indicating a potential upside of 148.86%. Sangamo Therapeutics has a consensus price target of $20.20, indicating a potential upside of 83.30%. Given Fusion Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Fusion Pharmaceuticals is more favorable than Sangamo Therapeutics.
Profitability
This table compares Fusion Pharmaceuticals and Sangamo Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Fusion Pharmaceuticals | N/A | -26.14% | -18.26% |
Sangamo Therapeutics | -51.51% | -16.32% | -9.85% |
Summary
Fusion Pharmaceuticals beats Sangamo Therapeutics on 6 of the 10 factors compared between the two stocks.